Co-transplantation of mesenchymal stem cells and HLA-mismatched allogeneic hematopoietic cells after nonmyeloablative conditioning: a phase II randomized double-blind study.
Clinical use of mesenchymal stem cells for the prevention and treatment of graft rejection and graft-versus-host disease after allogeneic transplantation for hematologic malignancies
